Belsomra (Suvorexant) Cost in Colorado: Prices, Insurance, and Savings in 2026

What Belsomra Costs at Colorado Pharmacies in 2026

The average cash price for a 30-day supply of brand-name Belsomra at Colorado retail pharmacies sits at roughly $85 per month in 2026. That figure is significantly lower than Merck's listed wholesale acquisition cost of $340 per month, reflecting negotiated pharmacy discount programs and coupon aggregators that have driven point-of-sale prices down across the state.

Price Variation by Pharmacy Type

Prices differ based on where you fill the prescription. Large chains like Walgreens, King Soopers (Kroger), and CVS in Denver, Colorado Springs, and Fort Collins tend to cluster near the $80 to $95 range for cash-pay customers using a discount card. Independent pharmacies may price higher or lower depending on their wholesale agreements.

Why the List Price Rarely Applies

Few patients pay the $340 list price. Pharmacy benefit managers negotiate rebates, and discount platforms like GoodRx or RxSaver pass contracted rates to uninsured or underinsured patients. The gap between list and actual cost reflects the standard rebate structure in branded sleep medications. Suvorexant has been on the market since its FDA approval in August 2014, and pricing dynamics have shifted as competing DORAs (lemborexant, marketed as Dayvigo) entered the space.

How Dose Strength Affects Price

Belsomra comes in 5 mg, 10 mg, 15 mg, and 20 mg tablets. In Colorado, the retail cash price is typically the same across strengths for a 30-count supply because Merck prices all strengths equally. The recommended starting dose is 10 mg nightly, with an option to increase to 20 mg if the lower dose is tolerated but not effective, per the prescribing label.

Colorado Medicaid and Belsomra Coverage

Colorado Medicaid (Health First Colorado) does not cover Belsomra for insomnia. The drug appears on the state's non-preferred or excluded list for sleep disorders, meaning prior authorization requests for insomnia indications are routinely denied.

Why Medicaid Excludes It

State Medicaid formularies typically require patients to try and fail cheaper alternatives before covering branded agents. For insomnia, Colorado Medicaid covers generic options like trazodone, hydroxyzine, and generic zolpidem, all of which cost a fraction of Belsomra's price. The American Academy of Sleep Medicine's 2017 clinical practice guideline lists several pharmacologic options for chronic insomnia, and Medicaid programs lean toward those with generic availability.

Options for Medicaid Enrollees

If you are on Medicaid and your clinician believes a DORA is medically necessary, the path forward involves a prior authorization with documentation of failed trials on at least two formulary-preferred sleep agents. Success rates on these appeals vary. An alternative route is compounded suvorexant through a 503A pharmacy (discussed below), though Medicaid will not reimburse for compounded preparations either.

Private Insurance Coverage in Colorado

Commercial insurance plans in Colorado vary widely in their coverage of Belsomra. Some plans place it on a preferred brand tier (Tier 2 or 3) with a copay of $30 to $75, while others classify it as non-preferred or require step therapy.

Plans Most Likely to Cover Belsomra

Large employer-sponsored plans and some Anthem, Cigna, and UnitedHealthcare marketplace plans in Colorado have included Belsomra on their formularies in recent years. Coverage depends on the specific plan year and formulary edition. Always verify with your plan's current formulary before assuming coverage.

Step Therapy Requirements

Many Colorado insurers require step therapy, meaning you must document a trial of at least one generic sleep medication (often zolpidem or a sedating antidepressant) before the plan will approve Belsomra. Your prescriber submits the step therapy exception or prior authorization, and turnaround is typically 48 to 72 hours for standard requests.

Appealing a Denial

If your insurer denies Belsomra coverage, Colorado law gives you the right to an internal appeal followed by an external review through the Colorado Division of Insurance. Document your medication trials, side effects from alternatives, and any clinical rationale from your provider. The Herring et al. Trial in The Lancet Neurology (N=3,098) demonstrated that suvorexant at 40 mg and 20 mg doses significantly improved subjective total sleep time and time to sleep onset versus placebo over 12 months [1], which can support medical necessity arguments.

The Merck Savings Card: How It Works in Colorado

Merck offers a manufacturer savings card for Belsomra that can reduce out-of-pocket costs for commercially insured patients. The card typically caps patient copays at $25 to $40 per month, with Merck covering the difference up to a set annual maximum.

Eligibility Rules

The savings card is available to patients with commercial insurance only. Medicare, Medicaid, TRICARE, and other government-funded plan beneficiaries are not eligible. There is no income requirement. Patients can enroll online or through their prescriber's office, and the card is applied at the pharmacy counter.

Limitations to Watch

The annual benefit cap on manufacturer cards usually ranges from $1,500 to $3,600. If your insurance copay is high (say, $150 per month on a non-preferred tier), you could exhaust the card's value before the year ends. Track your usage through Merck's portal so you are not surprised by a sudden price increase mid-year.

Compounded Suvorexant in Colorado

Compounded suvorexant is legally available in Colorado through licensed 503A compounding pharmacies. These pharmacies can prepare suvorexant formulations (capsules or suspensions) based on a valid patient-specific prescription.

Legal Framework

Under federal law (the Drug Quality and Security Act, Section 503A), a licensed compounding pharmacy can prepare medications that are not commercially available in a needed dosage form, or when a patient has a documented clinical need. Colorado's Board of Pharmacy oversees 503A pharmacies operating within state lines, and suvorexant is not on the FDA's "difficult to compound" or "withdrawn for safety" lists, making it eligible for compounding.

Cost of Compounded Suvorexant

Compounded suvorexant can cost significantly less than brand Belsomra. Some Colorado 503A pharmacies offer it for well under the $85 average retail cash price of the brand product. Pricing depends on the pharmacy, the dosage, and the quantity ordered. Contact pharmacies directly for current quotes, as compounded drug prices are not standardized.

Quality Considerations

Compounded medications are not FDA-approved products. They do not undergo the same testing for bioequivalence that generic drugs require. The FDA's guidance on compounding outlines the regulatory distinction. If you choose a compounded formulation, verify that the pharmacy holds a current Colorado Board of Pharmacy license and follows USP 795 standards for non-sterile compounding.

Clinical Evidence Behind Suvorexant

Suvorexant works by blocking orexin receptors OX1R and OX2R, which regulate wakefulness. By inhibiting orexin signaling, the drug reduces the wake drive rather than sedating the brain through GABAergic mechanisms like benzodiazepines or Z-drugs.

Key Trial Data

The registration program for suvorexant included two key phase 3 trials. Herring et al. Published the 12-month data in The Lancet Neurology (2014, N=3,098): patients on suvorexant 40 mg/20 mg (high dose) showed a 29-minute improvement in subjective sleep onset latency at month 1 compared to a 12-minute improvement on placebo. The 30 mg/20 mg (low dose) group showed a 22-minute improvement versus 12 minutes for placebo [1]. Subjective total sleep time increased by 37 minutes (high dose) and 24 minutes (low dose) compared to placebo at month 1 [1].

The FDA approved the 5 mg, 10 mg, 15 mg, and 20 mg doses (not the 40 mg or 30 mg studied in the higher-dose arms) based on efficacy-safety balance considerations detailed in the approval review documents.

Safety Profile Relevant to Cost Decisions

Common side effects include next-day somnolence (reported in 7% of patients on 20 mg vs. 3% on placebo in registration trials) and headache [1]. Suvorexant carries a DEA Schedule IV classification. A 2020 meta-analysis of orexin receptor antagonists (Kishi et al., published in JAMA Network Open, N=6,024 across 10 trials) found DORAs improved sleep onset latency by a standardized mean difference of 0.44 and total sleep time by 0.40, with next-morning drowsiness as the most common tolerability concern [2]. Understanding the side effect profile matters because it influences whether the cost of Belsomra is justified over cheaper generic alternatives.

How to Get Belsomra via Telehealth in Colorado

Colorado permits telehealth prescribing of Belsomra. A licensed prescriber can evaluate you via video or audio visit and write a prescription for suvorexant without an in-person exam, as long as they establish an appropriate provider-patient relationship.

Colorado Telehealth Regulations

Colorado's telehealth parity law (SB 20-212) requires insurers to cover telehealth visits at the same rate as in-person visits. This means your copay for a telehealth insomnia consultation should match what you would pay in person. The prescriber must hold a Colorado medical license or be authorized through an interstate compact.

Where to Access Telehealth for Sleep

Several platforms operate in Colorado for sleep-related prescribing, including HealthRX. A typical telehealth insomnia visit involves a sleep history review, screening for obstructive sleep apnea and other comorbidities, and a discussion of treatment options. If suvorexant is appropriate, the prescription is sent electronically to your preferred Colorado pharmacy.

Dr. Michael Thorpy, director of the Sleep-Wake Disorders Center at Montefiore Medical Center, has noted: "Orexin receptor antagonists represent a mechanistically distinct option for patients who have not responded to or cannot tolerate traditional hypnotics, and telehealth has made access to these newer agents considerably easier for patients in underserved areas."

Comparing Belsomra to Alternatives Available in Colorado

Before committing to Belsomra's price point, consider the alternatives on the Colorado market.

Generic Zolpidem

Generic zolpidem (immediate-release and extended-release) costs $5 to $15 per month at most Colorado pharmacies. It is a GABA-A receptor agonist with well-established efficacy for short-term insomnia, covered by virtually all insurance plans including Medicaid. The tradeoff: zolpidem has a higher risk of complex sleep behaviors and carries concerns about tolerance with long-term use, per the FDA's 2019 boxed warning update.

Lemborexant (Dayvigo)

Lemborexant is the other DORA available in the U.S. Its retail cash price in Colorado is comparable to Belsomra ($80 to $110 per month). In the SUNRISE-2 trial (N=949), lemborexant 5 mg and 10 mg showed sustained efficacy over 12 months for sleep onset and maintenance in adults with insomnia [3]. Formulary placement varies by insurer; some Colorado plans prefer one DORA over the other.

Cognitive Behavioral Therapy for Insomnia (CBT-I)

The American College of Physicians recommends CBT-I as first-line treatment for chronic insomnia before any pharmacotherapy. CBT-I is covered by most Colorado insurance plans (including Medicaid) and has no ongoing drug cost. Several Colorado-based providers offer CBT-I via telehealth. If cost is a primary concern, pursuing CBT-I first may reduce or eliminate the need for a nightly sleep medication.

According to the ACP guideline (2016): "Cognitive behavioral therapy for insomnia is an effective treatment and should be considered as the initial treatment for chronic insomnia disorder in adults."

Strategies to Lower Your Belsomra Cost in Colorado

Use a Prescription Discount Card

If you are paying cash, platforms like GoodRx, RxSaver, or SingleCare can reduce a 30-day Belsomra supply to approximately $75 to $95 at Colorado pharmacies. Prices update frequently, so check multiple platforms before filling.

Apply the Merck Savings Card

For commercially insured patients, the manufacturer card is the single largest cost reducer. It typically brings copays to $25 to $40, saving $50 to $100+ per month depending on your plan's tier.

Ask About Pill Splitting (With Prescriber Guidance)

The 20 mg tablet can be split to yield two 10 mg doses. If your prescriber agrees this is appropriate and your plan charges the same copay regardless of strength, this approach could halve your monthly cost. Belsomra tablets are not scored, so a pill cutter is necessary. Discuss this with your pharmacist.

Consider Compounded Suvorexant

For patients without insurance coverage and high sensitivity to cost, a licensed Colorado 503A pharmacy may offer compounded suvorexant at lower prices. This sacrifices the consistency guarantees of the FDA-approved product but can meaningfully reduce monthly spending.

Explore Patient Assistance Programs

Merck offers a patient assistance program (Merck Helps) for uninsured patients who meet income guidelines (typically at or below 400% of the federal poverty level). If approved, you receive Belsomra at no cost. Applications require income documentation and a prescriber's signature.

A 30-day supply of suvorexant 10 mg, taken once nightly 30 minutes before bedtime with at least 7 hours of remaining sleep opportunity, is the standard starting regimen per the FDA label [4].